TRIANGEL touts 1470nm laser for varicose vein treatment

TRIANGEL is promoting a 1470nm diode laser platform for endovenous treatment of varicose veins and venous reflux, saying the system is designed to reduce thermal injury and bruising. The company also highlights FDA clearance, CE MDR certification and more than 1,000 clinical cases with reported long-term occlusion rates above 98%.

Why it matters: - Varicose vein procedures depend on sealing diseased veins while limiting damage to surrounding tissue. - TRIANGEL is positioning its 1470nm system as a more precise option than earlier 980nm platforms that relied more heavily on hemoglobin targeting. - The company says the approach is meant to reduce vein wall perforation, ecchymosis and recovery time.

What happened: - TRIANGEL said it developed a 1470nm diode laser system for endovenous laser ablation of varicose veins and venous reflux. - The company said the platform is intended for ambulatory surgical settings and outpatient vein centers. - TRIANGEL also said the system uses selective endothelial water absorption and radial energy emission to create venous occlusion.

The details: - TRIANGEL said the 1470nm wavelength has an absorption coefficient about 40 times higher than 980nm for low-energy endothelial photocoagulation. - The company said surgeons typically use 50 to 70 joules per centimeter of linear endovenous energy density with the 1470nm approach. - TRIANGEL said the workstation supports 1 to 17 watts of continuous and pulsed laser delivery. - TRIANGEL said pulse widths range from 1 to 10,000 milliseconds. - The system uses 400 and 600 micrometer silica core radial fibers with sterile single-use packaging and SMA905 connectors, according to TRIANGEL. - TRIANGEL said a 650nm red aiming beam provides subcutaneous transillumination during fiber withdrawal. - The platform is designed to work with standard 5F and 6F micro-puncture vascular introducer sheath sets. - TRIANGEL said its radial fiber uses a fused silica refractive prism to convert the beam into a 360-degree conical ring of energy. - TRIANGEL said the design distributes energy evenly along the endothelial surface and helps avoid focal wall perforation. - TRIANGEL said the treatment preserves surrounding sensory nerves and adjacent tissues through lower thermal exposure. - TRIANGEL said the company operates under ISO 13485 standards and holds FDA clearance and Medical CE certification. - TRIANGEL said it maintains an ISO 13485:2016 quality system with 12 quality specialists. - TRIANGEL said it offers direct factory sourcing, customized user interface branding, clinical training support and sterile fiber delivery. - TRIANGEL said worldwide door-to-door delivery is available within two weeks. - The company directed readers to the official TRIANGEL medical engineering portal for optical specifications, clinical case reports and procurement quotations.

Between the lines: - The release is as much a product pitch as a clinical summary. - The strongest claims center on lower thermal damage and stronger procedural control, which are key differentiators in vein ablation. - TRIANGEL is also signaling manufacturing and procurement advantages, not just clinical ones. - The company’s reliance on observational data and partner-hospital experience suggests the core evidence base is presented as real-world performance rather than a randomized trial.

What's next: - TRIANGEL is inviting vascular surgeons, interventional radiologists and procurement directors to evaluate the platform. - The company appears to be pushing broader adoption through direct sales, training and technical support. - Further clinical validation would likely focus on comparative outcomes against older endovenous systems.

The bottom line: - TRIANGEL is betting that a 1470nm radial laser can deliver safer vein closure with less bruising, faster recovery and strong long-term occlusion rates.